Inyx, Inc. (IYXI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerInyx, Inc. (IYXI) trades at $0.0001. Inyx, Inc. is a specialized pharmaceutical company operating through subsidiaries in the US, Canada, and Europe. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for IYXI: IYXI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Inyx, Inc. (IYXI) Healthcare & Pipeline Overview
Inyx, Inc. is a specialized pharmaceutical company focused on developing and manufacturing prescription and over-the-counter medications across North America and Europe. Its expertise lies in advanced drug delivery systems, including hydrocarbon aerosols and various inhaler types for respiratory, dermatological, and cardiovascular applications, alongside offering pharmaceutical development consulting services.
What Is the Investment Thesis for IYXI?
Inyx, Inc. operates within the specialized pharmaceutical sector, focusing on advanced drug delivery systems and generic aerosol pharmaceuticals. A key value driver is its significant investment in research and development, particularly for inhalation-therapy devices and generic non-CFC/HFA respiratory inhalants, which positions it to potentially capitalize on evolving environmental regulations and demand for more efficient drug delivery. The company's high gross margin of 93.0% indicates strong pricing power or efficient production once products reach market, despite a current negative profit margin of -6.3%. This suggests that operational scale or successful product launches could significantly impact profitability. Growth catalysts include the successful development and commercialization of its proprietary product candidates, such as non-CFC respiratory inhalants and anti-inflammatory nasal pumps, which could open new market segments or capture market share from existing products. The provision of specialized pharmaceutical development and manufacturing consulting services also offers a stable, high-margin revenue stream, leveraging its core expertise without direct product market risks. However, as an OTC Other tier stock with an unknown disclosure status and a market capitalization of $0.00B, the company faces substantial risks related to liquidity, regulatory scrutiny, and access to capital, which are critical considerations for investors assessing its long-term viability and growth trajectory.
Based on FMP financials and quantitative analysis
IYXI Key Highlights
Gross Margin: 93.0%, indicating strong cost control relative to revenue from products sold.
- Profit Margin: -6.3%, reflecting current operational losses despite high gross margins, suggesting significant R&D or overhead expenses.
- Employee Base: 572 employees across operations in the US, Canada, and Europe, supporting its specialized pharmaceutical activities.
- Market Capitalization: $0.00B, indicating a very small or illiquid market valuation.
- OTC Tier: Trades on the OTC Other tier, signifying heightened risks related to disclosure and liquidity compared to major exchanges.
Who Are IYXI's Competitors?
IYXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | — |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | — |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IYXI's Key Strengths?
Specialized expertise in advanced drug delivery systems (aerosols, inhalers).
- High gross margin of 93.0% indicates efficient production or strong pricing power.
- Diversified product pipeline including generic and proprietary candidates.
- Revenue stream from specialized pharmaceutical consulting services.
What Are IYXI's Weaknesses?
Negative profit margin of -6.3% indicates current unprofitability.
- Market capitalization of $0.00B suggests very limited market valuation or liquidity.
- OTC Other tier listing implies significant regulatory and liquidity risks.
- Unknown disclosure status on the OTC market creates transparency challenges.
What Are the Key Risks for IYXI?
Negative profit margin of -6.3% indicates ongoing operational losses, raising concerns about long-term financial sustainability without improved profitability.
- The "OTC Other" tier classification and "Unknown" disclosure status present significant and ongoing risks related to liquidity, transparency, and regulatory scrutiny.
- Failure to secure necessary regulatory approvals for its pipeline products could delay or prevent market entry, impacting future revenue streams.
- Intense competition within the pharmaceutical industry, particularly from larger players with greater resources for R&D and market penetration.
- Dependence on successful commercialization of specialized drug delivery systems and generic aerosol pharmaceuticals, which face inherent development and market adoption risks.
What Threats Does IYXI Face?
- Intense competition from larger, more established pharmaceutical companies.
- Stringent and evolving regulatory requirements for drug development and manufacturing.
- High R&D costs and potential for product development failures.
- Risks associated with OTC Other tier trading, including limited investor interest and capital access.
What Are IYXI's Competitive Advantages?
- Specialized Manufacturing Capabilities: Expertise in complex drug delivery systems like hydrocarbon aerosols, metered-dose, and dry-powder inhalers, which require specific technical know-how and infrastructure.
- R&D Focus on Niche Areas: Dedicated research into advanced inhalation-therapy devices and non-CFC/HFA propellants, creating a potential first-mover or early-adopter advantage in these evolving segments.
- Regulatory Expertise: Navigating the stringent regulatory pathways for pharmaceutical products in the US, Canada, and Europe for both prescription and OTC drugs.
- Consulting Arm: Leveraging internal expertise to provide external consulting services, creating an additional, potentially high-margin, revenue stream and reinforcing industry connections.
What Does IYXI Do?
Inyx, Inc., established in 2000 with its principal offices in New York, New York, operates as a specialized pharmaceutical firm through its wholly-owned subsidiaries across the United States, Canada, and Europe. The company's core business revolves around the creation and production of both prescription and over-the-counter (OTC) medications. Inyx possesses robust production capabilities, particularly in the realm of hydrocarbon aerosols, which are utilized for dermatological and topical drug delivery. Furthermore, it manufactures a diverse range of inhaler types, including metered-dose and dry-powder inhalers, specifically engineered to address various respiratory conditions. The company's product portfolio also encompasses metered-dose nasal and throat pumps and sprays, as well as sterile saline solutions and injectable products, broadening its reach within the healthcare market. A significant portion of Inyx's strategic focus and investment is directed towards extensive research and development (R&D) initiatives. These efforts are primarily aimed at advancing inhalation-therapy drug delivery devices and methods, reflecting a commitment to innovation in a critical therapeutic area. This R&D emphasis also includes the development of generic prescription and OTC aerosol pharmaceuticals designed for a wide array of applications, such as respiratory, allergic, dermatological, topical, and cardiovascular conditions. The company is actively developing several proprietary product candidates. These include generic non-chlorofluorocarbon (CFC) or hydrofluoroalkane (HFA) respiratory inhalants, available in both single and combination drug formulations, alongside non-CFC propelled oral sprays targeting cardiovascular disorders. Additionally, Inyx is innovating with wound irrigation and cleansing sprays that incorporate advanced barrier technologies, and anti-inflammatory nasal pumps. Beyond its product development and manufacturing, Inyx leverages its specialized pharmaceutical expertise to offer development and manufacturing consulting services to the global healthcare sector, providing an additional revenue stream and strategic engagement opportunity. The company employs 572 individuals, contributing to its operational scope across multiple geographies.
What Products and Services Does IYXI Offer?
- Develops and manufactures prescription and over-the-counter (OTC) medications.
- Produces hydrocarbon aerosols for dermatological and topical drug delivery.
- Manufactures metered-dose and dry-powder inhalers for respiratory conditions.
- Creates metered-dose nasal and throat pumps and sprays.
- Produces sterile saline solutions and injectable products.
- Conducts significant R&D in inhalation-therapy drug delivery devices and methods.
- Develops generic non-CFC/HFA respiratory inhalants and other aerosol pharmaceuticals.
- Offers specialized pharmaceutical development and manufacturing consulting services globally.
How Does IYXI Make Money?
- Product Sales: Generates revenue from the manufacturing and sale of its proprietary and generic prescription and over-the-counter medications, including aerosols, inhalers, and injectables.
- Consulting Services: Provides specialized pharmaceutical development and manufacturing consulting services to other global healthcare sector entities, leveraging its expertise for a fee.
- R&D-driven Product Pipeline: Invests in research and development to create new proprietary product candidates and generic versions of existing drugs, aiming for future commercialization and market share capture.
What Industry Does IYXI Operate In?
Inyx, Inc. operates within the dynamic and highly regulated Medical - Pharmaceuticals industry, a segment of the broader Healthcare sector. This industry is characterized by continuous innovation, stringent regulatory pathways, and a constant demand for effective therapeutic solutions. Key market trends include the increasing prevalence of chronic respiratory and dermatological conditions, driving demand for advanced drug delivery systems, and a global push towards environmentally friendlier propellants like non-CFC/HFA in aerosols. The competitive landscape is fragmented, comprising large multinational pharmaceutical companies, specialized biotech firms, and generic drug manufacturers. Inyx positions itself by focusing on niche areas such as hydrocarbon aerosols, various inhaler types, and generic aerosol pharmaceuticals, aiming to differentiate through specialized drug delivery technologies and R&D in areas like non-CFC inhalants. Its consulting services also place it in a unique position to leverage its expertise across the industry.
Who Are IYXI's Key Customers?
- Pharmaceutical distributors and wholesalers.
- Hospitals and healthcare providers.
- Retail pharmacies and drugstores.
- Other global healthcare sector companies seeking development and manufacturing consulting.
- Ultimately, patients requiring respiratory, dermatological, cardiovascular, and other specialized medications.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
11 transactions · 0 purchases, 11 sales, 0 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for Inyx, Inc. stands at 171.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.6%, showing how much profit it generates from its asset base. A current ratio of 0.45 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Inyx, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 14.52 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Inyx, Inc. has missed Wall Street's EPS estimate in 0 of its last 3 reported quarters — a recurring pattern of falling short of estimates.
Company Profile
Inyx, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Steven Handley. IYXI has traded publicly since 2003.
IYXI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IYXI Latest News
No recent news available for IYXI.
IYXI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IYXI.
Price Targets
Wall Street price target analysis for IYXI.
IYXI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IYXI; grades run from A+ (80-100) to F (below 30).
Leadership: Steven Handley
Chief Executive Officer
Steven Handley serves as the Chief Executive Officer of Inyx, Inc., overseeing a global workforce of 572 employees across its operations in the United States, Canada, and Europe. His leadership is central to the company's strategic direction in developing and manufacturing specialized prescription and over-the-counter medications.
Track Record: Under Steven Handley's leadership, Inyx, Inc. has maintained its focus on advanced drug delivery systems, including hydrocarbon aerosols and various inhaler types. His tenure has seen the company channel significant research and development efforts into advancing inhalation-therapy drug delivery devices and methods, as well as the development of generic non-CFC/HFA respiratory inhalants and other proprietary product candidates. He manages the company's operations across multiple international subsidiaries.
IYXI OTC Market Information
Inyx, Inc. trades on the OTC Other tier of the OTC Markets Group. This tier is typically reserved for companies that do not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB, or major exchanges such as the NYSE or NASDAQ. Unlike exchange-listed companies which must file regular reports with the SEC, companies on the OTC Other tier have significantly fewer disclosure obligations, leading to less transparency and often making it challenging for investors to access current financial and operational information. This tier is generally considered to carry the highest risk among OTC market segments due to limited information and potential for infrequent trading.
- OTC Tier: OTC Other
- Limited Public Information: Unknown disclosure status severely restricts access to financial and operational data, impeding informed investment decisions.
- Extreme Illiquidity: Very low trading volume and wide bid-ask spreads make buying and selling shares difficult and can lead to significant price volatility.
- Lack of Regulatory Oversight: Fewer reporting requirements compared to major exchanges or higher OTC tiers means less scrutiny and potential for market manipulation.
- Difficulty in Valuation: Absence of reliable financial data and analyst coverage makes fundamental valuation challenging, increasing investment uncertainty.
- Potential for Fraud: The OTC Other tier has historically been associated with a higher risk of fraudulent activities due to lax oversight.
- Verify all available company filings, if any, directly from the company or OTC Markets.
- Research any news releases or corporate actions published by the company.
- Assess the company's operational status and product pipeline through independent sources.
- Investigate management's background and any past regulatory issues.
- Understand the company's capital structure and any outstanding debt or equity raises.
- Evaluate the competitive landscape and market demand for its specific products.
- Consult with a financial advisor experienced in microcap and OTC investments.
- Established in 2000, indicating a history of operation.
- Operates through wholly-owned subsidiaries in US, Canada, and Europe, suggesting international presence.
- Engaged in specialized pharmaceutical development and manufacturing, a complex industry.
- Offers consulting services, leveraging specific industry expertise.
- Employs 572 individuals, indicating a substantial operational footprint.
What Investors Ask About Inyx, Inc. (IYXI) — Healthcare
What are the specific challenges and implications of Inyx, Inc. trading on the OTC Other tier?
Trading on the OTC Other tier presents several specific challenges and implications for Inyx, Inc. and its investors. Firstly, the "Unknown" disclosure status means there is a significant lack of publicly available financial and operational information, making it difficult for investors to conduct thorough due diligence and assess the company's true value or performance.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available beyond basic margins and market cap.
- CEO tenure years not provided in source data.
- OTC disclosure status is 'Unknown', impacting depth of analysis for financial transparency.